Teva Announces Approval And Launch Of Generic Urso 250(R) And Urso Forte(R)
Main Category: Liver Disease / HepatitisAlso Included In: Regulatory Affairs / Drug Approvals
Article Date: 19 May 2009 - 0:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
4.5 (2 votes) |
| Healthcare Prof: |  |
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) for Ursodiol Tablets USP, 250 mg and 500 mg. Teva's Ursodiol Tablets are the AB-rated generic equivalents of Axcan's Urso 250® and Urso Forte®, which are indicated for treatment of patients with primary biliary cirrhosis. Shipment of this product has commenced.
The brand product had annual sales of approximately $76 million in the United States for the twelve months that ended March 31, 2009, based on IMS sales data.
Source
Teva Pharmaceutical Industries Ltd
Visit our liver disease / hepatitis section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/150453.php>
APA
http://www.medicalnewstoday.com/releases/150453.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
